Tag: Market Research Report

Outsourcing: An Attractive Option For Antibody Production

In recent years, contract manufacturers have become an integral part of the overall biopharmaceutical market. This trend is also gaining popularity within the antibody therapeutics market, as developers are increasingly outsourcing their antibody production requirements to contract service providers. This can be attributed to the fact that employing such third-party service providers offers various advantages,

Large Volume Wearable Injectors: A breakthrough to simplify Chronic Disease Management

The last few years have witnessed a rising incidence of chronic illnesses across the globe. Long term clinical conditions, such as neurological disorders, cardiovascular disorders, chronic pain and oncological disorders, have been shown to impose a significant burden on the modern healthcare system and those who suffer from such diseases. It is reported that about

Significant Potential of Gut Flora: Human Microbiome

Human Microbiome Therapies are Viable Alternatives to Antibiotics, with Substantial Therapeutic Potential The term microorganisms was perceived to be synonymous to harmful, disease causing agents, until the discovery of certain beneficial microbial colonies in the human system. Currently, humans and a variety of species of bacteria, yeast and protozoa, are known to co-exist in mutually

The Evolving Dynamics of Large Volume Wearable Injectors Market

The field of self-injection devices has witnessed a lot of innovation in the recent years. Specifically, , large volume wearable injectors are certainly a boon due to their ability to address challenges associated with the administration of high volume formulations, viscous drug solutions and cater to frequent dosing requirements of patients suffering from chronic health

Fill / Finish Services Industry: Impact of the Swelling Biopharmaceutical Pipelines

Biopharmaceuticals represent the most rapidly growing and high-value segment of the pharmaceutical industry. Growing at an annualized rate of ~12%, the industry stands tall with more than 5,000 biologics in development and over 300 FDA approved biologics, since 2002. Biologic drug development is characterized by high quality standards and a rapidly growing demand for novel

In Vitro ADME Testing Services: Emerging Opportunities for Service Providers

According to the US Food and Drug Administration (USFDA), less than 10% of investigational new drug (IND) candidates progress beyond the submission of a new drug application (NDA); this implies that majority of the drug / therapy candidates fail to reach the market owing to unacceptable safety and efficacy profiles and the problems associated with

Increasing Prevalence of Chronic Diseases- Driving the Demand for Self-Administration Devices, Like Autoinjectors

Over the last decade, autoinjectors have emerged as a promising therapeutic commodity for safe administration of parenteral therapies. Patients who suffer from chronic diseases, such as diabetes, rheumatoid arthritis and multiple sclerosis, often require frequent dosing of medication which poses significant inconvenience to them for visiting proper healthcare centers. Hence, autoinjector devices enable such patients

Peptide APIs – A Deeper Look Into Contract Manufacturing Market

The recent years have portrayed the renaissance of peptide APIs, as pharma industry has once again turned its attention towards the potential of therapeutic peptides. Adoption of peptides as therapeutic agents have side-lined some of the earlier concerns associated with them, such as bioavailability, and has led to manufacturing of high-quality peptides in a larger

Increasing Rate of Drug Failure has Prompted the Drug Developers to Rely on CROs offering In Vitro ADME Testing Services for their Outsourcing Requirements

It is important to note that the process of drug discovery is extremely demanding, both in terms of capital and time. In fact, the overall amount spent on R&D initiatives in the pharmaceutical / biotechnology sector has increased from around USD 128 billion in 2008 to USD 165 billion in 2018. Moreover, only a small

Targeted Protein Degradation is Anticipated to Become a Major Therapeutic Modality in the Coming Decade

The targeted protein degradation approach is believed to possess the potential to unlock the undruggable proteome, which was traditionally considered to be inaccessible. Compared to conventional inhibition strategies, degradation offers several benefits, which include the opportunity to completely remove aberrant proteins and associated systemic malfunctions. As a result, targeted protein degradation-based therapeutics have generated enthusiasm